Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Mallinckrodt
Express Scripts
Johnson and Johnson
AstraZeneca

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA INC. (D.N.J. 2014)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA INC. (D.N.J. 2014)

Docket   Start Trial Date Filed 2014-05-16
Court District Court, D. New Jersey Date Terminated
Cause 35:271 Patent Infringement Assigned To Jerome B. Simandle
Jury Demand None Referred To Magistrate Judge Karen M. Will
Parties CADILA HEALTHCARE LIMITED; OTSUKA PHARMACEUTICAL CO., LTD.; ZYDUS PHARMACEUTICALS USA INC.
Patents 5,006,528; 7,053,092; 8,017,615; 8,580,796; 8,642,600; 8,642,760; 8,759,350
Attorneys AMY MEGAN HANDLER; BRIAN RONALD ZURICH; CHRISTOPHER P. SOPER; DAN FENG MEI; JOHN F. BRENNER; MELISSA ANNE CHUDEREWICZ; TRENT S. DICKEY; VINCENT R. LODATO
Firms Axinn, Veltrop & Harkrider LLP; Pepper Hamilton LLP
Link to Docket External link to docket
Small Molecule Drugs cited in OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA INC. (D.N.J. 2014)

Date Filed Document No. Description Snippet Link To Document
2016-02-19 151 Entry of Summary Judgment Concerning U.S. Patent No. 8,759,350, Certification of Judgment Under Rule 54… 16 May 2014 1:14-cv-03168-JBS-KMW Patent None District Court, D. New Jersey External link to document
2015-10-13 169 actions specifically include: U.S. Patent Nos. 5,006,528 (“the ’528 patent”), Case 1:14-cv-03168-JBS-KMW Document…’600 patent”), 8,642,760 (“the ’760 patent”), and 8,759,350 (“the ’350 patent” or the “Patent”). The…,092 (“the ’092 patent”), 8,017,615 (“the ’615 patent”), 8,580,796 (“the ’796 patent”), 8,642,600 (“…drug claimed in a patent or the use of which is claimed in a patent” prior to the patent’s expiration. …various patents covering Otsuka’s brand name aripiprazole product, Abilify®. 1 1 The patents asserted External link to document
2016-04-12 240 5,006,528 (“the ’528 patent”), 7,053,092 (“the ’092 patent”), 8,017,615 (“the ’615 patent”), 8,580,796 (“…(“the ’796 patent”), 8,642,600 (“the ’600 patent”), and 8,642,760 (“the ’760 patent”). …asserted claims of U.S. Patent No. 8,759,350 (hereinafter, “the ’350 patent”), to mean “a single dosage… 1 The patents asserted in these related infringement actions generally include: U.S. Patent Nos. 5,…series of related patents: three directed at Otsuka’s aripiprazole polymorph patents (the ’615, the ’ External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Merck
Boehringer Ingelheim
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.